Kala Bio (KALA) said Wednesday that Mark Iwicki has resigned as chief executive, effective immediately, but will continue to serve as board chair.
The clinical-stage biopharmaceutical company appointed President and Chief Operating Officer Todd Bazemore as interim CEO.
Kala Bio shares were down about 34% in recent trading.
Price: 7.11, Change: -3.77, Percent Change: -34.65